American CryoStem Launches New Consumer Website Design

RED BANK, NJ–(Marketwire – Jan 19, 2012) – American CryoStem Corporation (OTCQB: CRYO) announced today the launch of the Company’s redesigned website americancryostem.com. The new website is a sophisticated online destination showcasing the Company’s branding and marketing of its core “Collect Process and Store” consumer stem cell service.

The new website experience is centered on providing the consumer simple, easy to read information about Adult Stem Cells and CRYO’s long term adult stem cell storage service currently offered through a national network of physicians. “The decision to redesign the website to be more consumer friendly was an easy decision after CRYO’s successful media campaign launch that attracted over 11,000 new members. From the feedback we received, we knew it was time for an update,” explains Natalia Drulle, Creative Director.

As part of CRYO’s on-going marketing campaign the new site features a live chat function to answer questions concerning the Company’s products and services. “Adding this dynamic feature to the site experience is a useful tool to increase customer support and sales conversion,” says John DiFolco, Director of Marketing. “Our goal is to shorten the sales process and provide instant support as we participate in the Regenerative Medicine market where Adult Stem Cells are frequently the main focus of discussion.”

John Arnone, CEO, stated, “The launch of our new website is another step in offering our products and services directly to the consumer market. Having the ability to educate our clients and then refer them to participating physicians allows us to efficiently deliver our message to targeted areas of the country where our service is being adopted.”

About American CryoStem: The Company markets a core clinical processing platform for Adipose (fat) Derived Adult Stem Cells. The Company’s services provide for the collection, processing, and cryopreservation (long term storage) of adult stem cells, allowing healthy individuals to privately preserve their stem cells for future use in personalized and regenerative medicine at an affordable price. Adult Stem Cells treatments are currently being utilized to potentially heal one’s own body of diseases and chronic conditions. The Company’s proprietary platform provides streamlined and affordable processing and cryopreservation of Adipose Derived Stem Cells (ADSCs) and Adipose Tissue (AT) for autologous use.

American CryoStem Announces “ACS Laboratory Services”

RED BANK, NJ–(Marketwire -01/13/12)- American CryoStem Corporation (OTC.BB: CRYO.OB – News) announces the branding of “ACS Laboratory Services.”

As of January 2012 we have branded our adipose tissue processing facility “ACS Laboratory Services.” This new branding reflects the Company’s increasing commercialization of products and services developed for its proprietary clinical tissue processing methodologies. We have begun offering the first of these products for sale and license which are based on our granted patent (Cell Culture Media, Kits and Methods of Use,” (US 7,898,205 B2)). The product line is the first patented culture, growth and differentiation media specifically designed for use with adipose derived stem cells (ADSC) and is ideally suited for the conversion of new ADSC therapies from research to clinical application. The media is available in both research and clinical grade, in 100ml to 1 liter ready to use quantities. The product line includes undifferentiated growth media, and adipogenic, chondrogenic, and osteogenic differentiation media. The clinical grade media are free from animal (xenomorphic) serum and additives which make them ideally suited for the expansion and differentiation of ADSCs intended for clinical use.

We made our first commercial sale of our media products this month and have begun marketing to increase industry recognition and sales. We currently have a new website www.acslaboratories.com under construction to support this new product offering and all future products and services commercialized by ACS Laboratories.

David Moscatello, Chief Scientist, stated, “I am very excited to have begun offering these products to my colleagues working with ADSCs and believe that these products will assist them in the acceleration of their treatment development. We have additional products and services in various stages of development based on our patented technologies and core adipose tissue processing platform that will be unveiled during the coming year.”

John S. Arnone, CEO, stated, “We are very enthusiastic to be able to announce the commercialization and initial sales revenue from products developed from our recently issued patent. During 2011 we have been the beneficiary of increased dialogue and involvement from both doctors and researchers regarding our services and products under development. Our overall philosophy concerning the services offered by ACS Laboratories is to offer clinical grade products that are free from animal materials that can relieve some of the costs and the significant and increasing regulatory burdens for developers of cellular technologies. These burdens are evidenced in the U.S. Department of Health and Human Services and the FDA’s regulations and guidance for manufacturers and developers in relation to the inclusion of xenomorphic (animal) material in the manufacturing and marketing of new and existing cellular products.”

About American CryoStem: The Company markets a core clinical processing platform for Adipose (fat) Derived Adult Stem Cells. The Company’s services provide for the collection, processing, and cryopreservation (long term storage) of adult stem cells, allowing healthy individuals to privately preserve their stem cells for future use in personalized and regenerative medicine at an affordable price. Adult Stem Cells treatments are currently being utilized to potentially heal one’s own body of diseases and chronic conditions. The Company’s proprietary platform provides streamlined and affordable processing and cryopreservation of Adipose Derived Stem Cells (ADSCs) and Adipose Tissue (AT) for autologous use.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties.

These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

Does fat flow from the fountain of youth?

Juan Ponce de Leon is best known for his search for the fountain of youth. Though this story is probably more fiction than fact, and was attributed to him only after his death, the legend of the fountain of youth and the quest for it have persisted since the 16th century. It has proven to be as elusive as the Holy Grail.

I hear a lot of baby boomers (of which I am one) talk about aging and the quest to maintain their youthful look, mind and health. If only there was a magic elixir for the myriad problems we face in our advancing age. Well, perhaps there is something that can turn back the hands of time to some extent, a little bit of the fountain of youth if you will.

Adipose tissue has been found to be an easily accessible, abundant source of adult stem cells. These stem cells can be used to treat a broad range of medical and cosmetic conditions. If you look at our Resource Library, you’ll see a sampling of the potential applications of adipose derived stem cells, from growing new bone to aiding reconstructive procedures to mitigating the symptoms of multiple sclerosis. And, yes, adipose derived stem cells can help us look youthful too. You can have lipofilling and lipostructuring performed anywhere on your body. Isn’t this a dream come true? Take your fat from a place you don’t want it and put it somewhere you do! Who of us wouldn’t like to remove a few pounds of avoir du pois and apply it elsewhere?

All joking aside, the potential future medical applications for adipose derived stem cells are profound, and they are not that far off. Now is the dawn of the era of regenerative and personalized medicine. Most countries outside of the United States are already using adult stem cells to treat patients with myocardial infarctions, fistulizing Crohn’s disease, and to grow organs. Medical tourism, traveling to other countries to take advantage of treatments not yet routinely available in the United States, has become a booming industry in part because of regenerative and personalized medicine. It is only a matter of time before these therapies become available in the U.S.

So this brings to mind a question. What can I do now to prepare? Speaking for myself, I already have an answer. I will store my adult stem cells in the hope of using them later in the event of a medical ailment, or, in a more vain moment, when I want to reverse the visible “hands of time” with a cosmetic treatment. Not only will I store my own adult stem cells, but I will encourage my children to store theirs as well. After all, that one umbilical cord blood sample I keep may not be useful for all three of them, so why leave anything to chance? It is a bio-insurance that will give me some peace of mind as a mother. It is also a gift I will be giving to family and loved ones. What about you?

Angela M. Miele, DPM
Medical Science Liaison
American CryoStem

American CryoStem Awarded Patent for Cell Culture Media

RED BANK, NJ–(Marketwire – Sep 1, 2011) – American CryoStem Corporation (OTCBB: CRYO) announced the grant to it of a patent by the United States Patent Office (USPTO).

American CryoStem Corporation (the “Company”) has been awarded U.S. Patent Number 7,989,205, entitled “Cell Culture Media, Kits, and Methods of Use” (the “Patent”), by the USPTO. This Patent covers a unique product for cellular growth in the processing of adult stem cells. This is significant to the Company for the advancement of its research, clinical and cosmetic applications. The Company’s management believes that the Patent will support the Company’s efforts in its goal to establish itself as a leader in the preparation of autologous stem cells for use in regenerative medicine. The Patent includes a specific human formulation to overcome the concerns and issues prevalent in the FDA’s and other regulatory agencies’ guidance when using non-human biologic materials in the preparation of stem cells for human use.

John S Arnone, CEO, stated, “We are pleased to have the Patent granted to the Company by the USPTO. We believe the Patent will be instrumental to the industry based on its cellular growth properties and absence of non-human biologic material. Further, as stem cell and regenerative medicine advances in the United States, as it has globally, the Company is confident the Patent, together with our core technology and our intellectual property regarding methods, formulations, devices and products will allow us to enter into additional partnerships and collaborations with other industry participants. The Patent validates our corporate direction and enhances our strategy to obtain strong intellectual property protection.”

Anthony Dudzinski, COO, stated, “We believe the Patent on specie specific media gives the Company a unique market position by alleviating the significant regulatory requirements associated with products containing fetal bovine serum or other non-human biologic components. The Patent is important and will accelerate the development and commercialization of additional Company products and services. We are excited and very optimistic regarding our place in the stem cell industry and the value of our products and services.”

About American CryoStem: The Company markets a core clinical processing platform for Adipose (fat) Derived Adult Stem Cells. The Company’s services provide for the collection, processing, and cryopreservation (long term storage) of adult stem cells, allowing healthy individuals to privately preserve their stem cells for future use in personalized and regenerative medicine at an affordable price. Adult stem cell treatments are currently being utilized to potentially heal one’s own body of diseases and chronic conditions. The Company’s proprietary platform provides streamlined and affordable processing and cryopreservation of Adipose Derived Stem Cells and Adipose Tissue for autologous (self) use.